多发性骨髓瘤诊断时同时存在的肾功能损害的预后：系统评价。
Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review.
机构信息
Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.
Department of Clinical Laboratory, Taizhou Hospital, Zhejiang University, Linhai, China.
出版信息
Ann Med. 2024 Dec;56(1):2380301. doi: 10.1080/07853890.2024.2380301. Epub 2024 Jul 22.
BACKGROUND
Multiple myeloma is a malignant tumour of the blood in which abnormal proliferation of plasma cells leads to bone destruction, renal impairment, anaemia, and hypercalcaemia. Renal impairment caused by multiple myeloma is a common and serious condition; however, the prognosis of multiple myeloma at the time of diagnosis remains unclear.
METHOD
We conducted searches for literature in PubMed, Web of Science, Cochrane, Embase, CNKI, Wanfang, and VIP databases up to 30 April 2023. Progression-free survival and overall survival with and without renal impairment at the time of multiple myeloma diagnosis were compared, and prognostic indicators were analysed.
RESULTS
Six studies were finally included. Among patients with multiple myeloma, 319 had renal impairment, and 1166 had no renal impairment. Compared to the control group, no significant difference was observed in overall or progression-free survival in patients with multiple myeloma complicated with renal impairment.
CONCLUSION
The limited low-quality evidence available does not support an association between prognosis and multiple myeloma complicated by kidney injury.
背景
多发性骨髓瘤是一种血液恶性肿瘤，其中浆细胞异常增殖导致骨质破坏、肾功能损害、贫血和高钙血症。多发性骨髓瘤引起的肾功能损害是一种常见且严重的情况；然而，多发性骨髓瘤诊断时的预后仍不清楚。
方法
我们对截至 2023 年 4 月 30 日的 PubMed、Web of Science、Cochrane、Embase、CNKI、万方和 VIP 数据库中的文献进行了检索。比较了多发性骨髓瘤诊断时伴有和不伴有肾功能损害患者的无进展生存期和总生存期，并分析了预后指标。
结果
最终纳入 6 项研究。多发性骨髓瘤患者中，319 例有肾功能损害，1166 例无肾功能损害。与对照组相比，多发性骨髓瘤合并肾功能损害患者的总生存期或无进展生存期无显著差异。
结论
现有有限的低质量证据不支持多发性骨髓瘤合并肾损伤与预后相关。
Zotero 插件